Drug Research
Innovacyn introduces eye, ear formulations
Innovacyn, a provider of human and animal healthcare products, has added Vetericyn VF Ophthalmic Wash and Vetericyn VF Otic Rinse to its professional-strength animal healthcare line. The antimicrobial solution found in the Ophthalmic Wash and Otic...
Drug Research
Glenmark settles patent case with Daiichi, Genzyme
Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA). With this settlement, Glenmark can roll out its generic...
Drug Research
RxMD signs drug development agreement with GlycoRegImmune
RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI's novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory and neurodegenerative conditions. As per the terms of the agreement, RxMD will...
Drug Research
Evotec, Roche collaborate to develop oncology biomarkers
Evotec has entered into an oncology research and development agreement with Roche to organize multiple protein-activity based biomarker programs for Roche's therapeutic antibodies or small molecule inhibitors under development. Under the agreement, Evotec will use...
Drug Research
Evotec and PsychoGenics Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions
Evotec AG announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. The two companies will work together in a seamless fashion to provide existing...
Drug Research
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Drug Delivery of BA058
Radius Health, Inc. and 3M Drug Delivery Systems announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius’ novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis. ...
Drug Research
Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men
Amgen announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read